The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Updates from the CharisMMa study
Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, briefly discusses some results from the CharisMMa study (NCT03188536) investigating the sociodemographic characteristics of myeloma patients at relapse in Spain. Dr Ocio discusses some of the characteristics that were observed and how these may influence treatment decisions, such as employment, distance between a patient’s home and the hospital, and comorbidities. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
